



## **Profound Medical to Participate in A.G.P.'s Virtual Healthcare Conference**

**TORONTO, ON (May 18, 2023)** - [Profound Medical Corp.](#) (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in A.G.P.'s Virtual Healthcare Conference on Wednesday, May 24, 2023.

The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.

### **About Profound Medical Corp.**

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO<sup>®</sup>, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO<sup>®</sup> is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. TULSA-PRO<sup>®</sup> has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia ("BPH"). TULSA-PRO<sup>®</sup> is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration ("FDA").

Profound is also commercializing Sonalleve<sup>®</sup>, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve<sup>®</sup> has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve<sup>®</sup> where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

### **For further information, please contact:**

Stephen Kilmer  
Investor Relations  
[skilmer@profoundmedical.com](mailto:skilmer@profoundmedical.com)  
T: 647.872.4849